Vireo Growth Inc. (VREOF) generates a steady flow of news driven by its activities in the cannabis industry, including medical and adult-use operations, multi-state expansion, and corporate transactions. As a company that describes itself as a pioneering medical cannabis operator founded in 2014, Vireo uses press releases to communicate developments in its retail footprint, cultivation and production capacity, and strategic initiatives.
Recent news items highlight several key themes. One is geographic expansion and market entry. Vireo announced an Agreement and Plan of Merger to acquire Eaze Inc., a vertically integrated cannabis retailer and delivery technology platform with operations in California, Florida, and Colorado. The company states that this transaction is intended to mark its entry into California and Florida and to strengthen its position in Colorado, with Eaze becoming a wholly owned subsidiary upon closing.
Another recurring theme is M&A and capital structure activity. Vireo has reported entering into agreements to acquire a majority of Schwazze’s senior secured convertible notes, participating in a restructuring support agreement that contemplates an asset sale to a new entity to be majority-owned by Vireo, and negotiating an Asset Purchase Agreement to acquire Colorado dispensary assets from PharmaCann Inc. These announcements detail transaction terms, consideration in subordinate voting shares, and conditions such as regulatory approvals.
Operational updates also feature prominently. Vireo issued a release announcing the launch of adult-use cannabis sales in Minnesota at its Green Goods dispensaries, noting that it dispenses both medical and adult-use products at eight locations in the state. Quarterly earnings releases provide summaries of financial performance, state-by-state revenue, and non-GAAP metrics, accompanied by management commentary on integration of acquisitions and portfolio development.
Investors and observers who follow VREOF news can use this stream of announcements to monitor transaction progress, regulatory milestones, market entries, adult-use launches, litigation resolutions, and financial reporting updates, all of which are documented through Globe Newswire releases and linked SEC filings.
Vireo Growth (VREOF) announced that its property borrowers entered into US$60 million in financing for New York and Florida facilities. Approximately US$49 million of proceeds are being used to refinance existing senior debt connected to the Johnstown facility purchase option, and approximately US$11 million to finance acquisition of the Palatka facility supporting Green Dragon operations.
The loan bears 8.5% annual interest and matures on April 2, 2034. Security includes first-priority mortgages on both properties, pledged subsidiary membership interests and substantially all personal property of the borrowers and other loan parties. In connection with the Palatka acquisition, the existing Rainbow lease will be terminated and a new lease executed with Vireo affiliate Green Dragon Florida.
Vireo Growth (VREOF) entered a three-year put/call agreement with Battle Green Holdings SR to acquire a loan with US$18,096,028 principal.
The loan is evidenced by a note issued by BG Ohio SPV. Battle Green may require Vireo to purchase it with subordinate voting shares priced at US$19.50 each; Vireo may elect to purchase it with shares priced at US$18.60. Exercising either right would result in a maximum of 972,905 shares based on principal. If neither right is exercised by maturity, Vireo will acquire the note using shares priced at their trailing 30-day volume weighted average price, subject to CSE pricing minimums. Additional shares may cover accrued interest, although Vireo may pay interest in cash. No shares will be issued until a purchase right is exercised and all applicable conditions are satisfied.
Vireo Growth (VREOD) has closed its previously announced indirect acquisition of M3 Wellness, a dispensary in Hawthorne, Nevada, under an asset purchase agreement dated June 5, 2026.
The total transaction consideration was $500,000, with $290,000 paid in cash at closing. The remaining $210,000 was satisfied through the issuance of 13,888 subordinate voting shares of Vireo at a deemed issue price of $15.12 per share.
Vireo Growth (VREOD, VREOF) will issue 462,963 subordinate voting shares to SHWZ Altmore, LLC and Altmore Debt I, LP under a confidential settlement agreement related to Vireo’s acquisition of certain secured obligations and related liens held by Altmore.
The shares, defined as Settlement Shares, are being issued as consideration for the assigned interest pursuant to an assignment and assumption agreement. The Settlement Shares will be subject to a six‑month lock‑up period from issuance and resale restrictions, during which holders may not transfer the shares without Vireo’s prior written consent. All other settlement terms remain confidential.
Vireo Growth (VREOD, VREOF) plans to attend the ATB Cormark Capital Markets 2026 Life Sciences Fall Institutional Investor Conference on September 9, 2026, in New York City.
Chief Financial Officer Tyson Macdonald will hold one-on-one meetings with investors. The company’s current Q2 2026 investor presentation is available on its investor relations website.
Vireo Growth (CSE: VREO, OTCQX: VREOF) has completed its previously announced acquisition of all issued and outstanding shares of C21 Investments (CSE: CXXI, OTCQX: CXXIF) via a court-approved plan of arrangement under British Columbia law. C21 shareholders received 0.023052 Vireo subordinate voting shares for each C21 common share, resulting in the issuance of an aggregate 2,766,409 Vireo shares.
According to Vireo, the deal adds three Silver State Relief dispensaries and about 104,000 sq. ft. of cultivation and production, expanding its Nevada footprint to roughly 14 dispensaries and 159,000 sq. ft. of cultivation and manufacturing. C21 common shares are expected to be delisted from the CSE and OTCQX, and C21 plans to cease being a reporting issuer and deregister its shares in due course.
Vireo Growth (CSE: VREO, OTCQX: VREOF) received board authorization for a normal course issuer bid share buyback program starting August 17, 2026. The company may repurchase up to 2,426,872 subordinate voting shares on the Canadian Securities Exchange, with any repurchased shares to be cancelled.
As of August 13, 2026, Vireo Growth had 48,517,509 subordinate voting shares and 7,718 multiple voting shares outstanding, with the latter convertible into 771,800 subordinate voting shares. Purchases will be executed by Haywood Securities under an automatic repurchase plan that allows buying at prices up to US$18.75 per share, within preset parameters. The program runs until August 17, 2027 and may be amended, suspended or terminated; the company is not obligated to purchase any shares.
Vireo Growth (CSE: VREO, OTCQX: VREOF) reported Q2 2026 GAAP revenue of $209.3 million, up 335% year-over-year, with pro forma revenue of $254.9 million assuming recent acquisitions. GAAP gross profit rose to $95.3 million with a 45.5% margin, while non-GAAP adjusted EBITDA reached $41.5 million (19.8% margin).
Growth was driven by closing the Hawthorne, Eaze and Bridgewell deals and announcing acquisitions of FLUENT and C21, plus multiple post-quarter transactions including PharmaCann assets, Cannabist assets, four Ohio deals, and a merger agreement with Planet 13. Vireo ended Q2 with $122.7 million in cash, a new $65–105 million asset-based revolver, and approximately 54.4 million subordinate voting shares outstanding on a treasury-method basis.
Vireo Growth (CSE: VREO; OTCQX: VREOF; also associated with VREOD) announced that certain indirect non-cannabis subsidiaries have entered into a senior secured asset-based revolving credit facility with an initial $65 million commitment. The facility is expandable to $85 million and up to $105 million via a $20 million accordion feature, subject to customary conditions.
Borrowings bear interest at Term SOFR plus 1.75%–2.00% or base rate plus 0.75%–1.00%, depending on average availability, and include a 0.25% annual unused commitment fee. The five-year facility was arranged and led by Bank of Montreal and is secured by substantially all assets of the participating non-cannabis subsidiaries. According to Vireo, proceeds may be used to refinance existing subsidiary debt, fund working capital, capital expenditures, permitted acquisitions, and other general corporate purposes.
Vireo Growth (CSE: VREO, OTCQX: VREOF) has received all required regulatory approvals and completed its previously announced acquisition of certain Colorado retail assets from PharmaCann. Total consideration was approximately $49.0 million, paid through the issuance of Vireo subordinate voting shares and the assumption of certain liabilities, with final share consideration subject to customary closing adjustments under the Asset Purchase Agreement.
The acquired business comprises 17 dispensaries, increasing Vireo’s Colorado retail footprint to 56 operational locations. Since March 2026, Vireo had managed these PharmaCann assets under a Management Services Agreement, enabling early operational integration. With the transaction closed, the MSA concludes and the assets will be fully integrated into Vireo’s Colorado platform, where the company plans to pursue initiatives in operational excellence, margin expansion and long-term organic growth.